CROs Are Back, Many with Specialties

We’ve documented the increase in biotechnology acquisitions and license deals by pharmaceutical companies in previous posts. But the impact of pharma’s move away from in-house R&D has benefited other sectors of the healthcare industry, particularly clinical research organizations (CROs). For those outside the technology side of healthcare, CROs provide outsourced research services to the pharmaceutical, biotechnology, and medical device industries on a contract basis. Through mid-November, we’ve seen an increase of 325% in deal volume for CROs, compared with the year before. In 2015, just five deals for these targets were announced. So far this year, 17 are on the... Read More »